This disclosure relates to Compound (I), pharmaceutically acceptable salts, or pharmaceutically acceptable compositions thereof, for the treatment of CNS related disorders, e.g., tremor, e.g., essential tremor； depression； and anxiety disorder, and methods for improving the effectiveness of the administration of Compound 1 for treating said CNS related disorders. The disclosure also relates to methods of increasing the bioavailability of a Compound 1 or pharmaceutically acceptable salts, or pharmaceutically acceptable compositions thereof.
